| Status | Study |
| Not yet recruiting |
Study Name: A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR) Condition: Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR) Date: 2017-05-05 Interventions: Drug: ABBV-176 Intravenous infusion |
| Active, not recruiting |
Study Name: Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma Condition: Cushing Syndrome Adrenocortical Carcinoma Date: 2017-04-26 Interventions: Drug: Abiraterone Acetate Cohort 1: |
| Not yet recruiting |
Study Name: Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma Condition: Adrenocortical Carcinoma Peritoneal Carcinomatosis Date: 2017-04-02 Interventions: Drug: Cisplatin |
| Recruiting |
Study Name: Familial Investigations of Childhood Cancer Predisposition Condition: Acute Leukemia Adenomatous Polyposis Date: 2017-02-08 |
| Not yet recruiting |
Study Name: Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Condition: Adrenal Cortex Carcinoma Adult Alveolar Soft Part Sarcoma Date: 2016-08-15 Interventions: Drug: Cabozantinib S-malate Gi |
| Recruiting |
Study Name: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Condition: Acinar Cell Carcinoma Adrenal Cortex Carcinoma Date: 2016-07-13 Interventions: Procedure: Biospecimen Collection |
| Not yet recruiting |
Study Name: Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Condition: Functional Pancreatic Neuroendocrine Tumor Malignant Somatostatinoma Date: 2016-07-10 Interventions: Drug: Capecitabine Given PO |
| Recruiting |
Study Name: Study to Evaluate CORT125134 in Patients With Cushing's Syndrome Condition: Cushing's Syndrome Date: 2016-06-15 Interventions: Drug: CORT125134 |
| Recruiting |
Study Name: Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Condition: Advanced Cancers Date: 2016-03-23 Interventions: Drug: Pembrolizumab 200 mg by |
| Active, not recruiting |
Study Name: Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer Condition: Metastatic Carcinoma in the Adrenal Cortex Recurrent Adrenal Cortex Ca Date: 2016-03-16 Interventions: Other: Laboratory Biomarker Analysis |